儿童全面性发育迟缓检查的当前循证建议
该综述基于2006至2016年文献,为5岁以下全面性发育迟缓(GDD)患儿提供一线和二线检查建议。若已排除外源性病因,所有不明原因GDD患儿应一线进行基因检测;无论GDD严重程度,均应检查可治疗疾病,代谢病检查应作为一线。临床评估仍是指导检查的关键。
要点
- 不明原因GDD且无外源性病因的5岁以下患儿,基因检测应作为一线检查。
- 所有GDD患儿无论严重程度,均应筛查可治疗的代谢性疾病。
- 二线检查应根据病史、体格检查和发育轨迹个体化选择。
核心结论
- 不明原因GDD患儿若未确立外源性病因,基因检测应作为一线检查。
- 所有GDD患儿无论严重程度均应检查可治疗疾病,代谢病检查应作为一线。
研究设计与样本
- 本文为文献综述,检索2006至2016年文献,纳入5岁以下发育迟缓检查相关证据。
主要发现
- 可治疗疾病的检查阳性率高于既往认识。
- 二线检查可由病史、体格检查和发育轨迹引导。
关键数值与推荐
- GDD影响1%-3%的5岁以下儿童。
- 基因检测应作为不明原因GDD的一线检查。
- 可治疗代谢病检查应作为一线检查。
临床怎么用
- 对5岁以下不明原因GDD患儿,首先排除外源性病因后安排基因检测。
- 所有GDD患儿均应筛查可治疗的代谢性疾病。
- 根据病史、体格检查和发育轨迹选择二线检查。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Global developmental delay (GDD) affects 1%-3% of the population of children under 5 years of age, making it one of the most common conditions presenting in paediatric clinics; causes are exogenous, genetic (non-metabolic) or genetic (metabolic). Recent advances in biotechnology and genetic testing mean that the investigations available to perform for children under 5 years are increasing and are more sensitive than previously. This change in availability and type of testing necessitates an update in the recommendations for investigating GDD. METHODS: We conducted a review of the literature from 2006 to 2016 to identify articles with evidence relating to the investigation of developmental delay in children under the age of 5 years. We collated the evidence into first-line and second-line investigations and, where available, on their yield and cost implications. RESULTS: We have provided up-to-date guidance for first-line and second-line investigations for children with GDD under the age of 5 years. Recent evidence demonstrates that genetic testing for all children with unexplained GDD should be first line, if an exogenous cause is not already established. Our review of the literature demonstrates that all patients, irrespective of severity of GDD, should have investigations for treatable conditions. Evidence demonstrates that the yield for treatable conditions is higher than previously thought and that investigations for these metabolic conditions should be considered as first line. Additional second-line investigations can be led by history, examination and developmental trajectories. DISCUSSION: We may need to update present recommendations in the UK for investigation of developmental delay. This would include microarray testing as first line and a more thorough approach to investigations for metabolic disorders that can be treated. Clinical assessment remains vital for guiding investigations.
引用
- Mithyantha R, Kneen R, McCann E, et al. Current evidence-based recommendations on investigating children with global developmental delay. Arch Dis Child. 2017. PMID: 29054862. doi:10.1136/archdischild-2016-311271
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。